December 10-13, 2011, San Diego, CA - Researchers from the Bing Center for WM attended the 53rd Annual ASH Meeting and Exposition. There they delivered 5 oral presentations including findings from the first whole genome sequencing project for WM, and continuing investigations into the MYD88 signaling pathway, and expression of Oct-2, Spi-B, and Id2/Id1.

Three posters were also presented, showcasing the latest research in the areas of bortezomib-containing regimens, MicroRNA studies, and a multicenter study of the MTOR inhibitor Everolimus (RAD001).

For more information about the American Society of Hematology (ASH) 54th annual meeting and exposition, please visit their website at http://www.hematology.org/Meetings/Annual-Meeting/

ASH 2011: Bing Center Oral Presentations

Click the hyperlink to download the abstract for the presentation

Lian Xu: A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

Steven Treon: Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom’s Macroglobulinemia

Zachary Hunter: Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia

Yangsheng Zhou: Aberrant Expression of Oct-2, Spi-B, and Id2/Id1 Is Associated with Repression of Plasma Cell Differentiation in Waldenström’s Macroglobulinemia

Guang Yang: Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom’s Macroglobulinemia

ASH 2011: Bing Center Poster Presentations

Click the hyperlink to download the full-size poster as a PDF file

Steven Treon: Treatment with a bortezomib-containing regimen is associated with better therapeutic outcomes in patients with Waldenstrom’s Macroglobulinemia who have familial disease predisposition.

Yang Cao: MicroRNA-21 and -155 are induced by a widely expressed mutation in MyD88(L265P) in Waldenstrom’s Macroglobulinemia.

Christina Tripsas: Prospective, Multicenter Study of the MTOR inhibitor Everolimus (RAD001) as Primary Therapy in Waldenstrom’s Macroglobulinemia.